GLP-1 coverage is being dropped by employers: 2027 weight-loss options
With open enrollment season in swing, many employees may notice something conspicuously missing from their benefits menu —…
Eli Lilly (LLY) earnings Q3 2026
Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales…
Cramer: I asked tech insiders what to buy. They said Eli Lilly
Jim Cramer said Monday that even tech-focused people think the world of Eli Lilly stock, with one predicting…
Novo’s Wegovy pill improves weight loss after switch from injections
People who switched from obesity injections to Novo‘s new Wegovy pill continued to lose weight after three months,…
Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since…
Lilly is ramping up future manufacturing for Foundayo obesity pill
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking…
Novo Nordisk rebrands to ‘Novo’ under CEO Mike Doustdar
Novo Nordisk on Monday said it is rebranding its name to “Novo” and updating its corporate culture, as…
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes…
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Wall Street analysts just called this healthcare stock a buy — here’s our take
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…